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Background: asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF), an agent selectively
damaging the tumour vasculature, showed a biphasic dose–response curve in preclinical models. Previous phase I
trials of NGR-hTNF indicated 0.8 and 45 lg/m
2 as optimal biological and maximum-tolerated dose, respectively.
Patients and methods: Two sequential cohorts of 12 colorectal cancer (CRC) patients who had failed standard
therapies received NGR-hTNF 0.8 or 45 lg/m
2 in combination with capecitabine–oxaliplatin (XELOX).
Results: Median number of prior treatment lines was 3 in the low-dose and 2 in the high-dose cohort. Overall, 21
patients had been pretreated with oxaliplatin-based regimens. No grade 3–4 NGR-hTNF-related toxicities were
observed. Grade 1–2 chills were reported in 43% and 40% of cycles in the low-dose and high-dose cohorts,
respectively. In the low-dose cohort, one patient achieved a partial response and ﬁve had stable disease for a median
of 4.6 months. In the high-dose cohort, six patients had stable disease for a median of 3.6 months. Three-month
progression-free survival (PFS) rates were 50% and 33% in the low-dose and high-dose cohort, respectively. Three
patients in low-dose cohort experienced PFS longer than PFS on last prior therapy.
Conclusions: Both NGR-hTNF doses were safely combined with XELOX in pretreated CRC patients. Hint of activity
was apparent only with low-dose NGR-hTNF.
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introduction
Over the past decade, major advances in the treatment of
metastatic colorectal cancer (CRC) have occurred with the
introduction of active chemotherapy combination (by adding
either oxaliplatin or irinotecan to 5-ﬂuoruracil) and targeted
agents given either as ﬁrst-line combination with chemotherapy
(bevacizumab or cetuximab) or as single-agent salvage therapy
(cetuximab or panitumumab). With these new drugs, there has
been a paradigm shift with a doubling of median survival over
5-ﬂuoruracil alone and a potential for long-term survival in
certain patients [1]. Despite the growing number of options in
ﬁrst and subsequent lines, most patients develop resistance to
these therapies [2]. Therefore, new treatment options are
needed to continue the progress achieved in this decade.
NGR-hTNF is a vascular targeting agent consisting of human
tumour necrosis factor-a (TNF) fused with the peptide
asparagine–glycine–arginine (NGR), an aminopeptidase N
(APN, CD13) ligand able to target tumour blood vessels [3–5].
The functional role of APN in promoting the angiogenic
development of newly formed blood vessels from pre-existing
blood vessels was recently conﬁrmed in a CD13-null murine
model [6]. Preclinically, NGR-hTNF induced stronger
antitumour effects than TNF even with 30 times lower doses
and displayed a biphasic dose–response curve showing
anticancer activity when given either at very low or at high
doses [2, 6].
In early-stage clinical development, a phase I study, testing
doses from 0.2 to 60 lg/m
2, established the maximum-tolerated
dose of NGR-hTNF at 45 lg/m
2 once every 3 weeks [7]. To
further explore the low-dose range from 0.2 to 1.6 lg/m
2,
a separate trial indicated 0.8 lg/m
2 as optimal biological dose
mainly based on pharmacodynamic (PD) end points such as
soluble TNF receptors (sTNF-Rs) kinetics and dynamic
imaging assessment [8]. Across all dose levels, NGR-hTNF
showed a favourable toxicity proﬁle, most common toxicities
being mild-to-moderate, short-lived, and infusion time-related
chills. Recently, NGR-hTNF given as single agent at 0.8 lg/m
2
was evaluated in 33 metastatic CRC patients who had
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this heavily pretreated patient population, a disease control rate
of 39%, a median progression-free survival (PFS) of 2.5
months, and a median survival of 13.1 months were reported
[9].
By damaging the integrity of cancer-associated endothelial
cell barrier, TNF is also able to quickly reduce the interstitial
ﬂuid pressure, a process considered pivotal to increase the
tumour-selective uptake of chemotherapy. Consistently, both
signiﬁcant preclinical synergism [10, 11] and safe clinical
toxicity proﬁle [12, 13] were observed by combining very low
doses of NGR-hTNF with multiple chemotherapeutic agents.
The current study was designed to primarily assess the safety
of low-dose (0.8 lg/m
2) and high-dose (45 lg/m
2) NGR-hTNF
in combination with ﬁxed doses of capecitabine plus oxaliplatin
(XELOX) in CRC patients who had previously failed standard
treatments. Secondary study aims included tolerability,
pharmacokinetics (PKs), PDs, and preliminary activity.
patients and methods
eligibility criteria
Study population included patients >18 years who had metastatic CRC.
They could have received no more than three prior treatment regimens,
including irinotecan, oxaliplatin, ﬂuoropyrimidine, and biological agents,
given in any combination or sequence in the adjuvant or advanced disease
settings. Additional eligibility requirements included Eastern
Cooperative Oncology Group performance status (PS) of zero to one,
absolute neutrophil count >1.5 · 10
9/l, platelet count >100 · 10
9/l, total
bilirubin <1.5 · upper limit of normal (ULN), aspartate and alanine
aminotransferase <2.5 · ULN in absence of liver metastasis or <5 · ULN in
presence of liver metastasis, and serum creatinine <1.5 · ULN. Patients with
signiﬁcant cardiac, vascular or infectious diseases, uncontrolled
hypertension, prolonged QTc interval, cerebral metastases, or symptomatic
peripheral neuropathy of grade ‡1 were excluded as well as patients
completing systemic therapy within 4 weeks or having surgery within 2
weeks before treatment start. All patients signed a written informed consent
approved by the ethical committee of the participating institution.
Clinical trials.gov study identiﬁer was NCT00675012.
study design, treatment plan, and safety
This was a single-centre, single-arm phase I study evaluating two doses of
NGR-hTNF in combination with XELOX. Because study population
consisted of patients generally pretreated with systemic therapy,
chemotherapy doses slightly lower than standard were used for both
chemotherapeutic agents.
The ﬁrst cohort of patients (n = 12) received NGR-hTNF given i.v. in 1 h
at 0.8 lg/m
2, followed by oxaliplatin 100 mg/m
2 delivered as a 2-h i.v.
infusion on day 1 and oral capecitabine 825 mg/m
2 twice daily (equivalent
to a total daily dose of 1650 mg/m
2) for 14 days, with the ﬁrst dose taken
the evening of day 1 and last dose the morning of day 15. Cycles were
repeated on an every 3-week basis. The second cohort (n = 12) was treated
with NGR-hTNF administered at 45 lg/m
2, followed by oxaliplatin and
capecitabine administered as above.
The assessment of two sequential dose cohorts was considered more
appropriate than a randomised study design to fully explore before the
safety of the combination of chemotherapy with low-dose NGR-hTNF and
then the association with high-dose NGR-hTNF. Either dose of NGR-hTNF
evaluated in the two cohorts was considered safe in combination with
XELOX regimen if no more than 2 of 12 patients experienced dose-limiting
toxicity related to the experimental drug. The choice between the low dose
and the high dose of NGR-hTNF to be selected for further testing in
combination with XELOX was based on an overall assessment of safety,
tolerability proﬁle, and preliminary antitumour activity observed in the two
cohorts.
Toxicity was graded according to the Common Terminology Criteria for
Adverse Events, version 3.0. Dose modiﬁcation for chemotherapy was
applied according to standard clinical practice, while no NGR-hTNF dose
reduction was allowed. On recycling, patients should have recovered from
all treatment-related toxicities to grade 1 or less. If a patient was unable to
meet retreatment criteria, all drugs were delayed for 1 week for up to 3
weeks. At investigator’s discretion, in the presence of chills, prophylaxis
with paracetamol was given for the next NGR-hTNF cycles.
Tumour restaging was done every other cycle (6 weeks) according to
RECIST criteria. In case of stable disease or objective tumour response,
both capecitabine and oxaliplatin were given for up to six cycles, whereas
NGR-hTNF was continued until progressive disease, unacceptable toxicity,
or patient’s refusal.
PK and PD analysis
In selected consenting patients, PK blood sampling was performed on day 1
of the ﬁrst three cycles with samples drawn at baseline and on-treatment at
six time points after each infusion (20, 60, 90, 120, 180, 240, and 360 min).
NGR-hTNF and sTNF receptors 1 and 2 (sTNF-R1 and sTNF-R2) levels
were determined by using a validated enzyme-linked immunosorbent assay.
Maximum plasma concentration (Cmax) and area under the plasma
concentration–time curve (AUC) were estimated from plasma
concentration–time data using standard non-compartmental methods.
The PD variables determined for sTNF-R1 and sTNF-R2 were Emax
(maximum plasma concentration) and AUC. The levels of NGR-hTNF and
sTNF-Rs were baseline normalised by subtracting the time zero value to all
other time points values.
statistical methods
Descriptive statistics were provided using medians (with ranges) and means
(with standard deviations) for continuous variables and proportions for
categorical variables. All analyses were based on an intention-to-treat
principle. Kaplan–Meier estimates were computed for PFS, deﬁned as the
time elapsed between ﬁrst treatment and disease progression or death from
any cause. A post hoc explorative analysis was conducted by using the
growth modulation index (GMI), deﬁned as the ratio of either uncensored
or censored patient’s PFS time on current study treatment relative to
uncensored PFS time observed from the patient’s most recent prior
treatment, which served as the patient-speciﬁc historical control value
[14, 15]. To compare differences in sTNF-Rs as a function of dose, the
Mann–Whitney test was used. The degree of association between two
continuous variables was quantiﬁed by Spearman rank correlation coefﬁcient.
results
patients
From January to June 2008, 12 patients (7 men and 5 women)
with a median age of 57 years (range 40–73 years) and a PS of
zero (n = 11) or one (n = 1) were enrolled in the low-dose
cohort. Between July 2008 and May 2009, an additional 12
patients (8 men and 4 women) with a median age of 56 years
(range 43–65 years) and a PS of zero (n = 8) or one (n = 4) were
recruited in the high-dose cohort. All patients presented with
either clinical or radiologically documented progression at
entry into the trial. All but two patients had received prior
systemic therapy for metastatic disease with a median of 3
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0–4) in the high-dose cohort. Twenty-one patients (87%) had
been previously treated with an oxaliplatin-based regimen and
19 patients (79%) with at least one targeted agent.
safety
Globally, 44 cycles (median 3 and range 2–6) were delivered in
the low-dose cohort and 35 courses (median 2 and range 1–6)
in the high-dose cohort. In all the 24 enrolled patients,
treatment discontinuation was a result of radiologically
documented progressive disease either in target lesions (n = 7)
or in nontarget lesions (n = 12), symptomatic deterioration
(n = 2), declining of further treatment by the patient (n = 2),
and death due to rapid progression (n = 1).
No grade 3–4 adverse events (AEs) clearly related to NGR-
hTNF were observed in both study cohorts. Only 33 (17%) of
190 study-emergent AEs were considered related to NGR-
hTNF. Most frequently, they were grade 1–2 chills, experienced
by 10 patients during 19 cycles (43%) in the low-dose cohort
and 6 patients during 14 courses (40%) in the high-dose
cohort. These events were short lived and infusion related.
Most commonly reported AEs are listed in Table 1. The
combination was well tolerated without apparent difference in
either frequency or intensity of AEs by dose level. Three
patients experienced ﬁve grade 4 AEs. Regarding
chemotherapy-associated toxicity, a dose reduction was
required in three patients for 11 cycles (25%) in the low-dose
cohort and three patients for 8 cycles (23%) in the high-dose
cohort. Chemotherapy was discontinued early for toxicity in
one patient enrolled in the low-dose cohort.
PKs and PDs
Eight and two patients had ﬁrst-cycle PKs and PDs studies
completed in the low-dose and high-dose cohorts, respectively.
Maximum plasma concentration and AUC of NGR-hTNF
increased with dose (P = 0.03 for both). The mean Cmax values
of NGR-hTNF at doses of 0.8 and 45 lg/m
2 were 87 and 689
pg/ml, respectively, whereas the corresponding values of AUC
were 5032 and 48 576 pg · min/ml, respectively. PK parameter
estimates of NGR-hTNF in this study were generally within the
ranges predicted from previous phase I trials testing NGR-
hTNF alone either at high dose [7] or low dose [8] and in
combination with chemotherapy at low dose [12, 13].
NGR-hTNF exposure signiﬁcantly correlated with the AUC
of both sTNF-R1 (r = 0.79, P = 0.006) and sTNF-R2 (r = 0.81,
P = 0.005).
The concentration–time proﬁles of both receptors remained
scattered around baseline value at 0.8 lg/m
2, indicating no
signiﬁcant induction of circulating receptors by NGR-hTNF at
this dose level. Conversely, the mean AUC values of sTNF-Rs
resulted higher at 45 lg/m
2 than at 0.8 lg/m
2 (sTNF-R1: 546
versus 141 pg · min/ml, respectively, P = 0.11 and sTNF-R2:
1805 versus 315 pg · min/ml, respectively, P = 0.03). Although
the mean AUC values of sTNF-R2 were signiﬁcantly higher
than those of sTNF-R1 (613 versus 234 pg/ml, respectively,
P = 0.02), plasma exposure of both sTNF-Rs tended to inversely
correlate with patient’s progression-free intervals (r = 20.58,
P = 0.08 for both).
antitumour activity
Twenty-three patients reached their ﬁrst tumour restaging and
were assessable for response (Table 2), while one patient came
off study because of symptomatic deterioration just after the
ﬁrst cycle. A waterfall plot showing the maximal tumour
change in target lesions for each patient by dose level is shown
in Figure 1. In the low-dose cohort, one patient (8%) achieved
a partial response and ﬁve patients (42%) had stable disease for
a median duration of 4.6 months (range 4.3–8.0 months),
whereas in the high-dose cohort, six patients (50%) maintained
stable disease for a median time of 3.3 months (range 1.6–7.5).
PFS rates at 3 months were 50% [95% conﬁdence interval (CI)
22% to 78%) in the low-dose cohort and 33% (95% CI 7% to
59%) in the high-dose cohort. The GMI, deﬁned by patient’s
PFS time on current study treatment relative to his/her PFS
time on prior treatment, is shown in Figure 2. Three patients
treated with low-dose NGR-hTNF had longer PFS than the PFS
on prior therapy lines. There was no correlation between the
durations of PFS on the last previous treatment and the current
Table 1. Most frequent AE (worst grade per patient) during or shortly
after treatment
Any grade,
N
Grade 1,
N
Grade 2,
N
Grade 3,
N
AE/low-dose cohort
Chills 10 1 9 –
Nausea 5 4 1 –
Hypersensitivity 5 1 1 3
Abdominal pain 5 1 4 –
Paraesthesia 3 1 1 1
Pyrexia 3 3 – –
Fatigue 2 1 – 1
Anorexia 2 1 1 –
Pain 2 1 1 –
Vomiting 2 1 1 –
Duodenogastric reﬂux 2 1 1 –
AE/high-dose cohort
Nausea 8 3 5 –
Chills 7 1 6 –
Asthenia 6 2 4 –
Vomiting 5 2 2 1
Pain 5 2 3 –
Abdominal pain 4 – 4 –
Paraesthesia 4 3 1 –
c-glutamyltransferase
increased
3 ––3
Diarrhoea 3 2 – 1
Constipation 3 1 2 –
Hyperuricaemia 2 – – 1
Hyperglycaemia 2 – 1 1
Anorexia 2 1 – 1
Hypertension 2 1 1 –
Presyncope 2 1 1 –
Pyrexia 2 2 – –
Hiccups 2 2 – –
Weight loss 2 2 – –
Anxiety 2 2 – –
Oedema peripheral 2 2 – –
Annals of Oncology original article
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high-dose cohort).
discussion
This study has shown that both optimal biological and
maximum-tolerated doses of NGR-hTNF can safely be added to
XELOX with a well-tolerated and nonoverlapping toxicity
proﬁle in heavily pretreated CRC patients.
Most commonly reported toxicities were those expected
from the chemotherapy regimen; however, the experimental
drug also produced toxicity independently. The constitutional
symptoms associated with the infusion of NGR-hTNF were
mild-to-moderate in severity, short lived, and unrelated to
dose. Notably, only 17% of all study-emergentAEs were
considered clearly related to NGR-hTNF.
A further aim of this study was to evaluate the PD effect of the
experimental drug on circulating TNF receptors. Both receptors
for TNF can be proteolytically cleaved as soluble forms, with
their shedding kinetics being linearly correlated with the TNF
serum levels [16]. By competing for TNF with cell-surface
receptors, these circulating receptors might block its
bioavailability likely acting as physiological attenuators of TNF
activity. Consistent with data from previous clinical trials [7, 8,
12, 13], an early induction of TNF receptor shedding was
detected mainly following high-dose NGR-hTNF. Interestingly,
the receptor levels tended to inversely correlate with progression-
free times, thus supporting preclinical data suggesting the role of
sTNF-R2 in regulating NGR-hTNF activity [10].
Table 2. Patient demographics, prior treatments, and antitumour activity by dose levels
Patient no. No. cycles No. of prior regimens Best response to last regimen/
PFS (months)
Best response to current
regimen/PFS (months)
Low-dose cohort
1 6 1 PR/13.1 SD/5.0
2 2 2 SD/4.2 PD
32 4 P D P D
4 6 3 PD SD/8.0
5 2 3 SD/10.4 PD
62 2 P D P D
7 6 4 NA SD/4.6
8 4 1 SD/5.7 PR/1.5
9 6 2 PR/9.4 SD/4.6
10 2 3 SD/8.5 PD
11 2 3 NA PD
12 4 4 PD SD/4.3
High-dose cohort
1 2 2 SD/7.1 PD
22 3 P D P D
3 4 2 PR/13.1 SD/7.5
42 2 P D P D
52 2 P D P D
6 4 4 SD/5.0 SD/3.3
7 4 3 SD/5.9 SD/2.7
8 2 2 PD SD/1.6
92 0 – P D
10 4 4 PD SD/3.2
11 1 2 PD PD
12 6 0 – SD/5.7
Even though eligibility criteria required prior treatment with no more than three prior regimens, two patients (both in the high-dose cohort) who did not
have previously received systemic therapy and ﬁve patients (three in the low-dose cohort and two in the high-dose cohort) who had previously received four
regimens were, however, allowed to be enrolled and were included in the study analysis. Though measurable disease was not required by study protocol, all
patients presented with at least one measurable target lesion according to RECIST criteria.
No. cycles, number of treatment cycles administered in the current study; PFS, progression-free survival; NA, not assessed; PD, progressive disease; SD, stable
disease; PR, partial response.
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Figure 1. Waterfall diagram showing maximal change in target lesions per
patient by dose level.
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976 | Mammoliti et al. Volume 22|No. 4|April 2011Even though antitumour activity assessment was not the
primary end point of this small-size, single-arm combination
study, some comments about hint of activity are warranted
(Table 2 and Figure 2). In the high-dose cohort, no responses
were observed (Table 2). In addition, none of the stable diseases
observed in this cohort lasted longer than the PFS reported
from the previous treatment lines, suggesting very little if any
activity (Figure 2).
However, among the 12 patients treated with XELOX plus
low dose of NGR-hTNF, 6 had tumour growth control, 1 had
partial response, and 5 had stable diseases (Table 2), and 3 of
these had PFS longer than those reported for the previous
treatment, indicating unequivocal antitumour activity. The
patient number in this series is too low to conclude for
a sufﬁcient level of activity for phase III testing, but it is enough
for a more formal and complete phase II trial, with a larger
patient number. This is particularly true in the light of the
lower than standard capecitabine and oxaliplatin doses used
here and in consideration of the very favourable toxicity proﬁle
of NGR-hTNF. Current development plans include phase II
testing of this combination in ﬁrst line (with low dose of NGR-
hTNF and regular dose of XELOX). Consideration is also given
to the feasibility of more frequent NGR-hTNF administrating
(weekly).
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